GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

On its final day, Global Health Exhibition turned its focus to a new generation of health technology innovators with the winner of the event's Vision NextGen competition announced as local biotech ...

World Business Council for Sustainable Development (WBCSD) is collaborating with leading companies in the sector, with support from PwC UK, to develop a Roadmap to Nature Positive for the ...

GSK plc (NYSE:GSK – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock traders bought 25,931 call options on the stock. This is an increase of 446% compared ...

Haleon’s pilot run of the screener analyzed 1,500 pieces of creative for the Panadol pain relief brand across nine markets.

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, ...